Charged Dendrimer Nanoparticles for MDSC Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective means to target and modulate the suppressive activity of myeloid-derived suppressor cells (MDSCs) in cancer, which are immunosuppressive and contribute to tumor progression.
Innovation Solution
Development of nanoparticle-based compositions and methods using charged polymeric dendrimer conjugates specifically binding to IL4Rα on myeloid cells, delivering nucleic acids such as shRNA to modulate the suppressive activity of MDSCs, thereby repolarizing them into tumoricidal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current methods are used to target myeloid cells, then general delivery is achieved, but specific targeting of MDSCs is insufficient
Solution Approach 1:
The dendrimer nanoparticle is functionalized with specific peptide ligands (e.g., IL-4Rα targeting peptides) at its surface, creating local binding sites that specifically recognize and bind to receptors on MDSCs. This localized functionalization enables selective targeting of MDSCs while maintaining the overall nanoparticle structure for drug delivery
Solution Approach 2:
The invention creates a composite nanoparticle system combining charged polymeric dendrimers with bioactive peptide ligands and therapeutic nucleic acid payloads (siRNA, shRNA). This composite structure integrates targeting functionality (peptides), delivery capability (charged dendrimer), and therapeutic action (nucleic acids) into a single multifunctional platform
2Productivity
If nucleic acids are delivered to MDSCs, then suppressive activity is reduced, but delivery efficiency to specific cell types is insufficient
Solution Approach 1:
The dendrimer nanoparticle acts as an intermediary carrier that bridges the therapeutic nucleic acids and the MDSC target cells. The nanoparticle protects the nucleic acids from degradation, facilitates cellular uptake through endocytosis, and enables controlled release of the therapeutic payload specifically within MDSCs
Solution Approach 2:
The invention optimizes physical-chemical parameters of the dendrimer nanoparticle including surface charge density, size distribution (50-200 nm), and peptide ligand density to maximize cellular uptake efficiency while minimizing non-specific binding to non-target cells. These parameter optimizations enhance delivery efficiency and reduce off-target effects
3Reliability
If MDSC suppressive activity is reduced, then anti-tumor immunity is enhanced, but conversion to tumoricidal cells is insufficient
Solution Approach 1:
The nanoparticle delivers therapeutic nucleic acids (siRNA/shRNA) that preemptively silence genes responsible for MDSC suppressive function (e.g., STAT3, C/EBPβ, CCR chemokine receptors) before these cells can exert their immunosuppressive effects. This preliminary gene silencing prevents the development of suppressive phenotypes and promotes repolarization toward tumoricidal activity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively delivers nucleic acids to MDSCs, reducing their suppressive activity, promoting anti-tumor effects by converting them into tumoricidal cells, thereby inhibiting cancer cell proliferation and tumor progression.
Implementation Method 1
nanoparticle comprising a charged polymeric dendrimer conjugate to a peptide that specifically binds to a peptide expressed on myeloid cells
Data Source
AI summary
Described herein are nanoparticle-based compositions, kits and methods and platforms for delivering one or more nucleic acids to a myeloid cell.